Literature DB >> 27655660

Arthritis in children: comparison of clinical and biological characteristics of septic arthritis and juvenile idiopathic arthritis.

Camille Aupiais1,2,3, Romain Basmaci3,4,5, Brice Ilharreborde3,6, Audrey Blachier7, Marie Desmarest8, Chantal Job-Deslandre9,10, Albert Faye2,3,4, Stéphane Bonacorsi3,5,11, Corinne Alberti1,2,3, Mathie Lorrot2,3,4.   

Abstract

AIM: Childhood arthritis arises from several causes. The aim of this observational study is to compare the clinical and biological features and short-term outcome of different types of arthritis because they have different treatment and prognoses.
METHODS: Children <16 years of age hospitalised in a French tertiary care centre for a first episode of arthritis lasting for less than 6 weeks who underwent joint aspiration were retrospectively included. We performed non-parametrical tests to compare groups (septic arthritis (SA), juvenile idiopathic arthritis (JIA) and arthritis with no definitive diagnosis). The time before apyrexia or C reactive protein (CRP) <10 mg/L was analysed using the Kaplan-Meier method.
RESULTS: We studied 125 children with a sex ratio (M/F) of 1.1 and a median age of 2.2 years (range 0.3 to 14.6). SA was associated with a lower age at onset (1.5 years, IQR 1.2-3.0 vs 3.6 years, IQR 2.2-5.6), shorter duration of symptoms before diagnosis (2 days, IQR 1-4 vs 7 days, IQR 1-19) and higher synovial white blood cell count (147 cells ×103/mm3, IQR 71-227, vs 51 cells ×103/mm3, IQR 12-113), than JIA. Apyrexia occurred later in children with JIA (40% after 2 days, 95% CI 17% to 75%) than children with SA (82%, 95% CI 68% to 92%), as did CRP<10 mg/L (18% at 7 days, 95% CI 6.3% to 29.6% vs 82.1%, 95% CI 76.1% to 89.7%, p=0.01).
CONCLUSIONS: There were no sufficiently reliable predictors for differentiating between SA and JIA at onset. The outcomes were different; JIA should be considered in cases of poor disease evolution after antibiotic treatment and joint aspiration. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Entities:  

Keywords:  Arthritis, Infectious; Arthritis, Juvenile; Child; Diagnosis, differential

Mesh:

Substances:

Year:  2016        PMID: 27655660     DOI: 10.1136/archdischild-2016-310594

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  5 in total

1.  Synovial fluid cell counts and its role in the diagnosis of paediatric septic arthritis.

Authors:  K K Obana; R R Murgai; M Schur; A M Broom; A Hsu; R M Kay; J L Pace
Journal:  J Child Orthop       Date:  2019-08-01       Impact factor: 1.548

2.  C-Reactive Protein Level at Time of Discharge Is Not Predictive of Risk of Reoperation or Readmission in Children With Septic Arthritis.

Authors:  Maryse Bouchard; Lara Shefelbine; Viviana Bompadre
Journal:  Front Surg       Date:  2019-12-03

3.  Synovial-Fluid miRNA Signature for Diagnosis of Juvenile Idiopathic Arthritis.

Authors:  Nadége Nziza; Eric Jeziorski; Marion Delpont; Maïlys Cren; Hugues Chevassus; Aurélia Carbasse; Perrine Mahe; Hamouda Abassi; Pauline Joly-Monrigal; Eric Schordan; Alain Mangé; Christian Jorgensen; Florence Apparailly; Isabelle Duroux-Richard
Journal:  Cells       Date:  2019-11-26       Impact factor: 6.600

4.  A Neonatal Hip Septic Arthritis Caused by Klebsiella pneumonia at Hawassa University Comprehensive Specialized Hospital Neonatal Unit, Hawassa, Sidama, Ethiopia.

Authors:  Bezaye Nigussie; Aberash Eifa; Bereketab Tagesse; Worku Ketema
Journal:  Int Med Case Rep J       Date:  2021-07-13

5.  Differential Accumulation and Activation of Monocyte and Dendritic Cell Subsets in Inflamed Synovial Fluid Discriminates Between Juvenile Idiopathic Arthritis and Septic Arthritis.

Authors:  Maïlys Cren; Nadège Nziza; Aurélia Carbasse; Perrine Mahe; Emilie Dufourcq-Lopez; Marion Delpont; Hugues Chevassus; Mirna Khalil; Thibault Mura; Isabelle Duroux-Richard; Florence Apparailly; Eric Jeziorski; Pascale Louis-Plence
Journal:  Front Immunol       Date:  2020-07-31       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.